PROMETHEUS® Anser™ tests uniquely provide both serum drug and antibody levels any time during treatment, offering critical data that may help you optimize patient clinical response.

For IBD patients on infliximab or adalimumab

Guide patients away from biologic burnout

Anser™ helps you take biologics further.

PROMETHEUS® Anser™ tests uniquely provide both serum drug and antibody levels any time during treatment, offering critical data that may help you optimize patient clinical response.
Is your patient on the way to infliximab or adalimumab burnout?

Biologic burnout or something else?

- Does your patient have adequate therapeutic drug levels?
- Has your patient developed anti-drug antibodies?
- Does your patient have therapeutic drug levels, but inflammation is not TNF-driven?
- Does your patient have clinical symptoms that don’t correlate with active IBD?

Occurs in up to:
- 61% of IFX patients\(^1\)
- 44% of ADA patients\(^2\)

Not having answers may impair potential effectiveness of biologics\(^{1-12}\).
PROMETHEUS® Anser™ tests provide critical data that may help you optimize your IBD patient's clinical response

- Uniquely measure both serum drug and antibody levels in the presence of infliximab or adalimumab from one sample any time during treatment
- More cost-effective than empiric management

• High assay sensitivity, specificity, and accuracy
  - Fewer false positives/negatives than ELISA test
  • Verified with 4000+ clinical IBD patient samples

Helps you:

- Interpret your patient’s response to the biologic
- Avoid unnecessary drug intensification, costs, and potential side effects
- Tailor your treatment plan to help maximize duration of biologic therapy
- Make informed treatment changes
Provide essential information for multiple clinical scenarios

Order PROMETHEUS® Anser™ tests for IBD patients who have:

- **Breakthrough symptoms between infusions/injections**
  
  To help clarify if symptoms could be related to clearance, immunogenicity, or nondrug factors\(^{10}\)

- **Restarted treatment after a drug holiday\(^1\)**
  
  After reinitiation prior to 2nd or 3rd infusion/injection, and/or to help predict response to reintroduction\(^{17}\)

- **Infusion/delayed hypersensitivity reactions**
  
  To help clarify if reactions could be related to immunogenicity\(^{12,18}\)
Validated in multiple studies\textsuperscript{9,20,21}

Both serum drug and antibody levels correlated with disease activity\textsuperscript{9,20,21,*,†}

**Serum Drug Levels**

- **Infliximab** ≥ 3 µg/mL\textsuperscript{20,†}
- **Adalimumab** ≥ 5 µg/mL\textsuperscript{19,21,*}

**Predictive of significantly lower disease activity based on C-reactive protein (CRP)**\textsuperscript{9,20,21,*,†}

- Both antibody-positive infliximab and adalimumab samples were associated with increased CRP levels\textsuperscript{9,20,21,*,†}
- Antibodies to infliximab levels of > 9.1 µg/mL at loss of response was associated with unsuccessful intervention\textsuperscript{22,‡}

\textsuperscript{*}Results from 2 cross-sectional studies where serum from a total of 120 patients (66 CD and UC) were analyzed.

\textsuperscript{†}Results from 1,487 serum infliximab samples from patients on maintenance infliximab in 4 prospective, randomized clinical trials.

\textsuperscript{‡}Results from 1,232 serum samples from patients with Crohn’s disease (n=64) and ulcerative colitis (n=26). Likelihood ratio = 3.6, 82% specificity, 64% sensitivity, $P=0.003$. 

---

**PROMETHEUS\textsuperscript{®} Anser\textsuperscript{™} tests may help you maximize duration of biologic therapy**

Elevated CRP, sedimentation rate, and fecal calprotectin, but are clinically asymptomatic\textsuperscript{19}

To help clarify if inflammation markers could be associated with drug/antibody levels and/or to identify patients who may be at risk for future loss of response\textsuperscript{20}
Published algorithms for treatment of patients with clinical symptoms\textsuperscript{1,23}

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Drug</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>(-)</td>
<td>(-)</td>
<td>Consider increasing dose or decreasing dose interval</td>
</tr>
<tr>
<td>(-)</td>
<td>(+)</td>
<td>Assess disease activity</td>
</tr>
<tr>
<td>(+)</td>
<td>(-)</td>
<td>Consider switching to drug out of class</td>
</tr>
<tr>
<td>(+)</td>
<td>(+)</td>
<td>Consider switching to drug within class</td>
</tr>
<tr>
<td>(+)</td>
<td>(+)</td>
<td>Consider switching to drug out of class</td>
</tr>
</tbody>
</table>

Based on clinical experience, experts suggest if antibodies are positive, consider adding an immunomodulator in addition to other changes in therapy.

Know their levels with PROMETHEUS\textsuperscript{®} Anser\textsuperscript{™} tests. Build your plan.
Test reports provide actionable results

Ordering is easy

1. Complete a PROMETHEUS Anser Test Requisition Form and give it to your patient.

2. Make a copy of the patient’s insurance card and give it to your patient.

3. Instruct your patient to call 888-423-5227 to schedule a blood draw, if not performed in your office.
Anser™ tests provide critical data that may help you optimize your IBD patient’s clinical response:

- Uniquely measure both serum drug and antibody levels in the presence of infliximab or adalimumab from one sample any time during treatment.
- Avoid unnecessary drug intensification, costs, and potential side effects – More cost-effective than empiric management
- Tailor your treatment plan to maximize duration of biologic therapy
- Interpret your patient’s response to the biologic
- Make informed treatment changes

For your IBD patients on infliximab or adalimumab:

Use PROMETHEUS® Anser™ tests to help you take biologics further

References:

©2015 Société des Produits Nestlé S.A. Vevey, Switzerland. All rights reserved. ADA15001 02/15

A Nestlé Health Science Company

Prometheus diagnostic services provide important information to aid in the diagnosis and management of certain diseases and conditions. How this information is used to guide patient care is the responsibility of the physician. Assays and methods within these tests may be covered by one or more US pending or issued patents. For details, please go to www.prometheuslabs.com.